KYV-101 presents key market opportunities in autoimmune diseases like SPS and gMG through regulatory advancements, promising clinical efficacy, and unmet needs for novel therapies. It offers potential as a disruptor with first-to-market status in rare indications, supported by strong strategic positioning and development capabilities.

Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "KYV-101 Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com'soffering.

The KYV-101 market forecast, as reported in the "KYV-101 Sales Forecast, and Market Size Analysis - 2034" study, provides comprehensive insights into its potential in treating conditions like Myasthenia Gravis, Multiple Sclerosis, and others across the major global markets. The report details KYV-101's forecasted sales, mechanism of action, dosage, and regulatory milestones, while also analyzing competition and emerging therapies.

KYV-101 is an investigational CAR T-cell therapy developed by Kyverna Therapeutics, designed to target CD19+ B-cells. It utilizes a CAR T-cell process involving the ex vivo modification of patient T-cells to target and deplete pathogenic B-cells in autoimmune diseases. The therapy showed efficacy in early trials for gMG, demonstrating significant clinical score reductions, and maintains a manageable safety profile.

Key Factors Driving KYV-101 Growth

Registrational and Regulatory Advancement:
KYV-101 is advancing in clinical programs with US FDA alignment. In Stiff Person Syndrome (SPS), Kyverna completed enrollment in the KYSA-8 Phase II trial aimed to support a Biologics License Application by mid-2026. The KYSA-6 Phase II/III study for Generalized Myasthenia Gravis (gMG) reported positive interim data and aims to start Phase III enrollment by late 2025.

Positive Clinical Data:
Reports indicate promising outcomes: in gMG, all patients in KYSA-6 showed significant improvements post-KYV-101 infusion, especially those previously unresponsive to other therapies. KYV-101 demonstrated durable efficacy in autoimmune conditions, which suggests potential for SPS and other diseases.

Significant Unmet Need and Market Opportunity:
With no FDA-approved treatments for SPS, KYV-101 could be a pioneering therapy. In Myasthenia Gravis, where current treatments require long-term immunosuppression, KYV-101 offers a potential single-dose solution if successful.

Broad Potential Across Diseases:
KYV-101 is under evaluation in additional autoimmune diseases, including lupus nephritis through ongoing trials (KYSA-1 and KYSA-3) and in investigator-led studies for multiple sclerosis, rheumatoid arthritis, and systemic sclerosis. Emerging data supports KYV-101's potential across these conditions.